Answers are grounded in this paper and cite their sources.
Two patients with chronic motor neuropathy, high antiganglioside antibody (AGA) titers, and a declining response to IV immunoglobulins were treated with rituximab at a standard dose. The drug was well tolerated and effectively eliminated peripheral B cells (CD20+), but AGA titers continued significantly high. No clinical improvement was detected during the 1-year follow-up.
No takes yet. Share an insight, caveat, or question.
Rojas‐García et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: